Resources

Please see the resources below to learn more about the issues surrounding the use of biosimilars. 

Materials

May 5, 2017

Educational Video: Biosimilars - The Path to Approval

View BPC's educational video, "Biosimilars: The Path to Approval" to learn why biosimilars can never be precisely duplicated, how indication extrapolation works and more on the rigorous, but abbreviated path to approval. Doctors and patients can have a degree of confidence in the safety of biosimilars, yet will have much to learn as their use increases in the clinical practice.  Read More ›

April 27, 2017

The State of Biosimilars Policy: A White Paper from Biologics Prescribers Collaborative

The Biologics Prescribers Collaborative provides a white paper on "The State of Biosimilars Policy" to educate policy makers as they take actions to encourage the development of these medicines while protecting patient safety and the prescribers’ need for transparent medical data. BPC hopes to ensure that policies governing the approval and use of biosimilars are crafted carefully to include the latest science, reflect clinical best practice, and uphold patient safety. As prescribers of biologics, our unique and important perspective about their use is presented in this white paper, and we will continue to provide Congress and the Administration education to create the needed rigorous policy framework that will promote access to and safe use of biosimilars for the millions of patients in America who could benefit from these medicines.  Read More ›

April 11, 2017

Updated Handbook - The Biosimilar Promise: An Introduction for Prescribers

The Biologics Prescribers Collaborative is pleased to publish the 2nd edition of our educational handbook, which serves as an introductory primer to key biologic and biosimilar issues. The biosimilars age has arrived with the promise of an expanding array of therapeutic options for patients and physicians battling serious diseases and conditions. As prescribers of biologics, we believe that realizing the biosimilar promise requires awareness of the differences between biosimilars and generics, and among biologics themselves, as well as an understanding of the distinctive therapeutic choices they represent. This introductory handbook provides an overview of the key issues. Read More ›

May 3, 2016

Biosimilar Naming: Distinguishable or Disingenuous?

A guest post from Robert Yapundich, M.D. and Gregory Schimizzi, M.D. Read More ›

April 12, 2016

The Biosimilar Promise: An Introduction for Prescribers

The biosimilars age has arrived with the promise of an expanding array of therapeutic options for patients and physicians battling serious diseases and conditions. As prescribers of biologics, we believe that realizing the biosimilar promise requires awareness of the differences between biosimilars and generics, and among biologics themselves, as well as an understanding of the distinctive therapeutic choices they represent. This introductoary handbook provides an overview of the key issues. Read More ›